• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Canopy Growth Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    5/27/26 4:16:56 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $CGC alert in real time by email
    false --03-31 0001737927 Canopy Growth Corp 00-0000000 0001737927 2026-05-26 2026-05-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): May 26, 2026

     

    Canopy Growth Corporation

    (Exact name of registrant as specified in its charter)

     

     

     

    Canada   001-38496   N/A
    (State or other jurisdiction
    of incorporation)
      (Commission
    File Number)
      (IRS Employer
    Identification No.)

     

    1 Hershey Drive
    Smiths Falls, Ontario
    K7A 0A8
    (Address of principal executive offices) (Zip Code)

     

    (855) 558-9333

    (Registrant’s telephone number, including area code)

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class Trading
    Symbol(s)
    Name of each exchange
    on which registered
    Common Shares, no par value CGC The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company    ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

     

     

     

     

     

     

    Item 5.03Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

     

    On May 26, 2026, the Board of Directors (the “Board”) of Canopy Growth Corporation (the “Company”) approved By-Law No. 2 Advance Notice By-Law (the “Advance Notice By-Law”), which is an amendment to its current bylaws. The Advance Notice By-Law became effective upon its approval by the Board. However, pursuant to Section 103 of the Canada Business Corporations Act (the “CBCA”), the Board must submit the Advance Notice By-Law to the shareholders of the Company (the “Shareholders”) at the next meeting of Shareholders (the “Shareholders Meeting”). At the Shareholders Meeting, Shareholders may, by ordinary resolution, confirm, reject or amend the Advance Notice By-Law. If the Advance Notice By-Law is confirmed or confirmed, as amended, by the Shareholders at the Shareholders Meeting, the Advance Notice By-Law will continue in effect in the form in which it was so confirmed. If the Advance Notice By-Law is rejected by Shareholders at the Shareholders Meeting, the Advance Notice By-Law will cease to be effective from the date of such rejection, and no subsequent resolution of the Board to make, amend or repeal a by-law of the Company having substantially the same purpose or effect may be effective until it is confirmed by the Shareholders. The Company expects to submit the Advance Notice By-Law to Shareholders at its next annual general meeting of Shareholders, which is expected to take place in September 2026.

     

    The Advance Notice By-Law establishes a formal framework governing how Shareholders may nominate directors for election at annual or special meetings of Shareholders. Its purpose is to ensure an orderly, transparent nomination process by setting clear deadlines and detailed disclosure requirements. Subject to the CBCA, applicable securities laws and the articles of the Company, only individuals nominated in accordance with the Advance Notice By-Law are eligible for election at a meeting of Shareholders. Pursuant to the Advance Notice By-Law, nominations may be made (i) by the Board, (ii) by or at the direction or request of one or more Shareholders pursuant to a proposal made in accordance with the provisions of the CBCA, or a requisition of a Shareholders’ meeting by one or more of the Shareholders made in accordance with the provisions of the CBCA, or (ii) by a Nominating Shareholder (as such term is defined in the Advance Notice By-Law) who meets ownership and procedural requirements contained in the Advance Notice By-Law.

     

    To nominate a nominee for director, a Nominating Shareholder must, among other things, deliver a written notice containing specified information, as prescribed in the Advance Notice By-Law, to the Secretary of the Company as follows:

     

    ·in the case of an annual meeting of Shareholders, subject to limited exceptions, no later than the 90th day before the first anniversary of the previous year’s annual meeting of Shareholders; provided, however, if the date of the annual meeting of Shareholders is advanced more than 30 days prior to or delayed by more than 30 days after the anniversary of the preceding year’s annual meeting of Shareholders, notice by the Shareholder to be timely must be so received not later than the close of business on the later of the 90th day prior to such annual meeting of Shareholders or, if later than the 90th day prior to such annual meeting of Shareholders, the 10th day following the day on which public announcement of the date of such meeting of Shareholders is first made; and

     

    ·in the case of a special meeting of Shareholders called to elect directors, no later than the later of the 90th day prior to such special meeting of Shareholders or the 10th day after the public announcement of the date of such special meeting of Shareholders.

     

    Under the Advance Notice By-Law, adjournments or postponements of an annual or special meeting of Shareholders do not restart or extend the notice period referred to above.

     

    A valid notice must include extensive information about both the proposed nominee and the Nominating Shareholder, including, among other things, all the information that would be required to be disclosed in a dissident’s proxy statement or other filings required to be made in connection with solicitations of proxies for election of directors pursuant to the CBCA, the U.S. Securities Exchange Act of 1934, as amended, or any applicable securities laws.

     

    Shareholders must update their notice after the record date for the applicable meeting of Shareholders and again shortly before the meeting of Shareholders to ensure all information remains accurate. The Board retains discretion to waive any requirement of the Advance Notice By-Law.

     

    The foregoing description of the Advance Notice By-Law is qualified in its entirety by reference to the Advance Notice By-Law, which is attached hereto as Exhibit 3.1 and incorporated herein by reference.

     

     

     

     

    Item 9.01Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No.

      Description
    3.1   By-Law No. 2 Advance Notice By-Law
         
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      CANOPY GROWTH CORPORATION
         
      By:

    /s/ Thomas Stewart

       

    Thomas Stewart

    Chief Financial Officer

     

    Date: May 27, 2026

     

     

     

     

    Get the next $CGC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CGC

    DatePrice TargetRatingAnalyst
    3/27/2026Buy
    Canaccord Genuity
    11/10/2025Sell → Hold
    The Benchmark Company
    4/4/2023Underperform → Mkt Perform
    Bernstein
    11/2/2022$1.50Underperform
    Bernstein
    10/26/2022Sell → Hold
    Canaccord Genuity
    6/8/2022Market Perform → Underperform
    BMO Capital Markets
    3/22/2022Equal Weight → Underweight
    Barclays
    3/1/2022$14.00 → $9.00Equal-Weight
    Barclays
    More analyst ratings

    $CGC
    SEC Filings

    View All

    SEC Form PRE 14A filed by Canopy Growth Corporation

    PRE 14A - Canopy Growth Corp (0001737927) (Filer)

    7/17/26 4:25:14 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form S-8 filed by Canopy Growth Corporation

    S-8 - Canopy Growth Corp (0001737927) (Filer)

    6/17/26 7:50:48 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Canopy Growth Corp (0001737927) (Filer)

    6/15/26 7:06:39 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Canopy Growth Announces Participation at Upcoming Canaccord Genuity Growth Conference

    Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) announced it will be participating at the Canaccord Genuity Growth Conference in August 2026. Canopy Growth CEO Luc Mongeau will be presenting on Tuesday, August 11 at 12:00 p.m. The presentation will be publicly accessible via live webcast at https://event.summitcast.com/view/WuFmFdTcA9mVsUGHZJFU62/8jLaQ2EHsfTiWktFQKVomw, and archived for 180 days. Canaccord Genuity's 46th Annual Growth Conference is set to take place in Boston, MA from August 11-13, 2026 and aims to bring together institutional investors from across the globe with some of the best and most promising growth companies in the Technology,

    7/21/26 7:30:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Reports Fourth Quarter and Fiscal Year 2026 Financial Results; Delivers Q4 FY2026 Net Revenue Growth of 27% in Canada Medical and 68% in International Markets Cannabis

    Full-year 2026 growth driven by net revenue increases of 20% in Canada adult-use cannabis and 18% in Canada medical Completed acquisition of MTL Cannabis, positioning Canopy Growth as Canada's leading medical cannabis company by revenue Ended the fiscal year with $131.3M of net cash following strategic recapitalization completed in January 2026 Strategic decisions and financial discipline in FY2026 establish a foundation for acceleration and growth Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced its financial results for the three months ended March 31, 2026 ("Q4 FY2026") and the fiscal year ended March 31, 2026 ("FY2026"). All fi

    6/15/26 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Announces Claybourne's Frosted Flyers Wins 'Best Infused Pre-Roll' at 2026 Grow Up Awards

    Claybourne extends its market share momentum with expanded Frosted Flyers lineup One of Canada's fastest-growing cannabis brands adds new variety formats built for flavour, discovery and summer pre-roll season Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced that Claybourne's Frosted Flyers Variety Pack has been awarded Best Infused Pre-Roll at the 2026 Grow Up Awards, presented during the annual Grow Up Conference & Expo in Toronto. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608930080/en/Frosted Flyers Variety Pack Building on that recognition, the Company also anno

    6/8/26 7:30:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $CGC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Mongeau Luc bought $49,994 worth of shares (27,469 units at $1.82), increasing direct ownership by 3% to 812,368 units (SEC Form 4)

    4 - Canopy Growth Corp (0001737927) (Issuer)

    9/23/25 4:15:11 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Bayern Joseph sold $2,953 worth of shares (3,197 units at $0.92), decreasing direct ownership by 2% to 145,127 units (SEC Form 4) (withholding tax)

    4 - Canopy Growth Corp (0001737927) (Issuer)

    6/29/26 4:16:43 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Yanofsky Theresa sold $13,905 worth of shares (15,054 units at $0.92), decreasing direct ownership by 9% to 146,415 units (SEC Form 4) (withholding obligation)

    4 - Canopy Growth Corp (0001737927) (Issuer)

    6/29/26 4:16:14 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Atkins M Shan sold $2,953 worth of shares (3,197 units at $0.92), decreasing direct ownership by 2% to 146,517 units (SEC Form 4) to cover taxes

    4 - Canopy Growth Corp (0001737927) (Issuer)

    6/29/26 4:15:42 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Canopy Growth

    Canaccord Genuity initiated coverage of Canopy Growth with a rating of Buy

    3/27/26 8:46:41 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth upgraded by The Benchmark Company

    The Benchmark Company upgraded Canopy Growth from Sell to Hold

    11/10/25 8:33:16 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth upgraded by Bernstein

    Bernstein upgraded Canopy Growth from Underperform to Mkt Perform

    4/4/23 9:09:41 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Leadership Updates

    Live Leadership Updates

    View All

    'There's a Tweed for That': Canopy Growth Announces Tweed Brand Summer Campaign

    New window bags, improved potency, and sharper pricing arrive at retail Victoria Day long weekend Canopy Growth Corporation ("Canopy Growth", "Canopy" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced a refresh of Tweed, one of Canada's most recognizable cannabis brands, alongside a national summer campaign, "There's a Tweed for That." This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260423388138/en/The Tweed summer campaign launches over the Victoria Day long weekend, the traditional kickoff to the Canadian summer, spotlighting Tweed's updated portfolio, including three new flower strains and the popular Quickies pre-ro

    4/23/26 7:30:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Announces Storz & Bickel Executive Transition

    David Männer appointed Managing Director Jürgen Bickel, who co-founded and built Storz & Bickel into a global premium vaporization technology leader, passes the torch following 25 years of transformational leadership Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced the appointment of David Männer as Managing Director of Storz & Bickel, a subsidiary of Canopy Growth, effective April 1, 2026. Mr. Männer succeeds Jürgen Bickel, Storz & Bickel's Co-founder, who has decided to transition out of his role. Founded in 2001, Storz & Bickel has grown into a global leader in vaporization technology. Today, it sets the standard for innovation, p

    3/27/26 7:30:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Completes Acquisition of MTL Cannabis Creating Canada's Leading Medical Cannabis Business By Revenue

    This news release constitutes a "designated news release" for the purposes of Canopy Growth's prospectus supplement dated August 29, 2025 to its short form base shelf prospectus dated June 5, 2024 All financial amounts in this press release are expressed in Canadian dollars. Strengthens Canopy Growth's core Canadian platform, providing additional high-quality flower to support international growth Expected run-rate synergies of approximately $10 million within 18 months Canopy Growth's leadership team and operational depth strengthened through addition of MTL management team members Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) and MTL Cannab

    3/16/26 7:41:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Financials

    Live finance-specific insights

    View All

    Canopy Growth Reports Fourth Quarter and Fiscal Year 2026 Financial Results; Delivers Q4 FY2026 Net Revenue Growth of 27% in Canada Medical and 68% in International Markets Cannabis

    Full-year 2026 growth driven by net revenue increases of 20% in Canada adult-use cannabis and 18% in Canada medical Completed acquisition of MTL Cannabis, positioning Canopy Growth as Canada's leading medical cannabis company by revenue Ended the fiscal year with $131.3M of net cash following strategic recapitalization completed in January 2026 Strategic decisions and financial discipline in FY2026 establish a foundation for acceleration and growth Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced its financial results for the three months ended March 31, 2026 ("Q4 FY2026") and the fiscal year ended March 31, 2026 ("FY2026"). All fi

    6/15/26 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth to Report Third Quarter Fiscal 2026 Financial Results on February 6, 2026

    Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED, NASDAQ:CGC) will release its financial results for the third quarter fiscal year 2026 ended December 31, 2025 before financial markets open on February 6, 2026. Following the release of its third quarter fiscal year 2026 financial results, Canopy Growth will host an audio webcast with Luc Mongeau, CEO and Tom Stewart, CFO on February 6, 2026 at 10 AM Eastern Time (ET). Webcast Information A live audio webcast will be available at: https://onlinexperiences.com/Launch/QReg/ShowUUID=45C34153-5530-4D6A-A742-BC34AD2534FA Replay Information A replay will be accessible by webcast until 11:59 PM ET on May 7, 2026 at:

    1/23/26 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Reports Second Quarter Fiscal 2026 Financial Results; Company Continues to Strengthen Financial Performance with Improving Adjusted EBITDA, Disciplined Cost Management, and a Stronger Balance Sheet

    Canada adult-use revenue up 30% in Q2 FY2026 and 37% year-to-date, reflecting the benefits of our focused commercial strategy and more disciplined execution Canada medical revenue up 17% in Q2 FY2026 and 15% year-to-date, marking another standout quarter for growth $298MM cash and cash equivalents, which exceeds debt balances by $70MM at September 30, 2025; as a result, conditions that previously raised substantial doubt concerning the Company's ability to continue as a going concern have been resolved Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced its financial results for the second quarter ended September 30, 2025 ("Q2 FY2026"). Al

    11/7/25 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

    SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

    4/19/24 5:00:49 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

    SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

    11/3/23 4:30:53 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

    SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

    7/20/23 4:35:52 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care